ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0509

BRIGHT HD Brazil Research Investigation on Public Health Gain Comparing Survival Between Hemodialysis and Hemodiafiltration

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Luciano, Eduardo De paiva, Splendore Kidney Care, São Paulo, Brazil
  • Borges, Cynthia Moura, Splendore Kidney Care, São Paulo, Brazil
  • Cordeiro, Aline, Nefrostar Kidney Care, Campos do Jordão, SP, Brazil
  • Reis, Sandra, Nefrostar Kidney Care, Campos do Jordão, SP, Brazil
  • Andrade, Douglas Vega, Núcleo de Saúde FLMA/IRSSL, Campos do Jordão, SP, Brazil
  • Rocha, Whelington Figueiredo, Nefrostar Kidney Care, Campos do Jordão, SP, Brazil
  • Magalhães, Andréa Olivares, Nefrostar Kidney Care, Campos do Jordão, SP, Brazil
  • Elias, Rosilene M., Splendore Kidney Care, São Paulo, Brazil
Background

High-flux online hemodiafiltration (OL-HDF) appears to be associated with better survival than hemodialysis (HD). In Brazil, OL-HDF is only affordable for patients with private health insurance. Although observational studies have shown a survival advantage with OL-HDF, even in Brazil, it is unclear whether this benefit applies to patients without private health insurance. We compared overall and cardiovascular mortality between OL-HDF and HD in patients treated exclusively through the Public Health Care system.

Methods

This is an observational cohort study with adult patients on maintenance hemodialysis or OL-HDF in the study period between September 1, 2022, and December 1, 2024.
The primary outcome was all-cause mortality. The secondary outcome was cardiovascular mortality.

Results

Patients on HD were more likely to have diabetes (54.0% vs 29.2%, p 0.001) and spent more hours per week on dialysis (11.2 ± 1.8 vs. 10.5 ± 1.6 hours, p=0.006). In an adjusted Fine-Gray model, the hazard of death for patients on OL-HDF was 68% lower than that for patients on HD, and the risk of death for patients with an arteriovenous fistula was 55% lower compared to those with a catheter. Cardiovascular mortality did not differ between the groups.

Conclusion

These findings suggest that OL-HDF is associated with higher overall survival compared to HD, even for patients without private health insurance.

Digital Object Identifier (DOI)